GeNeuro joins the CAC® Mid & Small, CAC® Small and CAC® All-Tradable Euronext indexes

Regulatory News:

GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for autoimmune diseases including multiple sclerosis, announces its inclusion, as of today, in three new indexes from the Euronext CAC family: CAC^® Mid & Small, CAC^® Small and CAC^® All-Tradable.

The Expert Indices Committee of Euronext took the decision in its quarterly review of indices on June 9, 2016.

Miguel Payró, CFO of GeNeuro, said: "We are delighted that GeNeuro is now included in the CAC^® family of indexes, just a few months after our IPO on Euronext in Paris. The inclusion of GeNeuro shares in these indexes represents another step forward in our development as a listed company, giving us greater visibility among investors both in France and internationally."

About GeNeuro

GeNeuro‘s mission is to develop safe and effective treatments against neurological disorders and autoimmune diseases such as multiple sclerosis by neutralizing causal factors encoded by human endogenous retroviruses (HERV), which represent 8% of the human DNA; a new frontier pioneered by GeNeuro since 2006 based on 15 years of R&D at Institut Mérieux and INSERM.

GeNeuro's first product, GNbAC1, is a monoclonal antibody that could represent a paradigm shift in the options for treating multiple sclerosis. GNbAC1 is being developed under a collaboration agreement with Servier that could generate, excluding royalties, over €360 million in revenue for GeNeuro, €37.5 million of which is to be allocated to financing the ongoing Phase IIb clinical trial in this disease.

GeNeuro is based in Geneva, Switzerland and has R&D facilities in Archamps, Haute-Savoie and Lyon. It has 23 employees and rights to 16 patent families protecting its technology.

For more information, visit: www.geneuro.com

View source version on businesswire.com: http://www.businesswire.com/news/home/20160619005032/en/